ACHN-975 TFA is primarily utilized in the field of medical research, particularly in the study of bacterial infections. It functions as a potent inhibitor of the LpxC enzyme, which is crucial for the biosynthesis of lipid A in Gram-negative bacteria. By targeting this enzyme, ACHN-975 TFA effectively disrupts the bacterial cell wall synthesis, leading to the inhibition of bacterial growth and proliferation. This makes it a valuable tool in the development of novel antibiotics aimed at combating resistant strains of Gram-negative bacteria. Researchers employ ACHN-975 TFA in preclinical studies to evaluate its efficacy, safety, and potential therapeutic applications, paving the way for new treatments for infections caused by pathogens such as Pseudomonas aeruginosa and Escherichia coli.